B003 / Shanghai Pharma - LARVOL DELTA

B003 in Patients With HER2-positive Recurrent or Metastatic Breast Cancer (clinicaltrials.gov) - P1 | N=30 | Completed | Sponsor: Shanghai Pharmaceuticals Holding Co., Ltd | Active, not recruiting ➔ Completed | N=45 ➔ 30 | Trial completion date: Jul 2023 ➔ Jan 2023

Enrollment change • Metastases • Trial completion • Trial completion date • Breast Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Oncology • Solid Tumor

B003 in Patients With HER2-positive Recurrent or Metastatic Breast Cancer (clinicaltrials.gov) - P1 | N=45 | Active, not recruiting | Sponsor: Shanghai Pharmaceuticals Holding Co., Ltd | Recruiting ➔ Active, not recruiting

Enrollment closed • Metastases • Breast Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Oncology • Solid Tumor

B003 in Patients With HER2-positive Recurrent or Metastatic Breast Cancer (clinicaltrials.gov) - P1 | N=45 | Recruiting | Sponsor: Shanghai Pharmaceuticals Holding Co., Ltd | Trial completion date: Dec 2022 ➔ Jul 2023 | Trial primary completion date: Sep 2022 ➔ Dec 2022

Trial completion date • Trial primary completion date • Breast Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Oncology • Solid Tumor

B003 in Patients With HER2-positive Recurrent or Metastatic Breast Cancer (clinicaltrials.gov) - P1 | N=45 | Recruiting | Sponsor: Shanghai Pharmaceuticals Holding Co., Ltd | Trial completion date: Sep 2021 ➔ Dec 2022 | Trial primary completion date: May 2021 ➔ Sep 2022

Trial completion date • Trial primary completion date • Breast Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Oncology • Solid Tumor

[VIRTUAL] B003 MAKING FUNGAL INFECTIONS EXCITING AGAIN: PRESSING QUESTIONS IN PULMONARY AND CRITICAL CARE PRACTICE (ATS 2021) - "The objective of this symposium is to raise and attempt to answer five of the most challenging questions in the field of fungal infections as they pertain to pulmonary and critical care medicine in 2021. Learning Objective 1 understand the growing importance of Candida auris, an emerging pathogen, and appreciate the nuances of empirical therapy for novel and traditional species Learning Objective 2 refine the ability to diagnose invasive pulmonary aspergillosis in the immunocompromised host as well as in the immunocompetent critically ill patient Learning Objective 3 learn and appreciate the evolving understanding of the interplay between fungal infection and infection with SARS-CoV-2"

Critical care • Infectious Disease • Novel Coronavirus Disease • Pulmonary Disease • Respiratory Diseases

IGF-1R anti-idiotypic antibody antagonist exhibited anti-ovarian cancer bioactivity and reduced cisplatin resistance. (PubMed, Hum Cell) - "Ovarian cancer is the most deadly gynecological malignant tumor in the world today. In summary, our research shows that B003-2A can be used to treat ovarian cancer. The current study also laid the foundation for the development of IGF-1R antagonist."

Journal • Gynecologic Cancers • Oncology • Ovarian Cancer • Solid Tumor

A Study of SI-B003, a PD-1/CTLA-4 Bispecific Antibody, in Patients With Advanced Solid Tumors (clinicaltrials.gov) - P1; N=159; Recruiting; Sponsor: Sichuan Baili Pharmaceutical Co., Ltd.

Clinical • New P1 trial • Gastrointestinal Cancer • Oncology • Solid Tumor

First Report of Xanthomonas fragariae Causing Angular Leaf Spot on Strawberry (Fragaria x ananassa) in Taiwan. (PubMed, Plant Dis) - "First, bacterial DNA of four candidate isolates, B001, B003 and B005 from Miaoli County and B004 from Taoyuan City, was PCR amplified with X. fragariae-specific primers: XF9/XF12 (Roberts et al...To our knowledge, this is the first report of X. fragariae causing angular leaf spot on strawberry in Taiwan. Currently, the disease only occurs severely in certain regions, but establishment of effective management strategies will be needed to prevent spreading of this disease and potential economic loss in the future."

Journal • Infectious Disease

Ningiella ruwaisensis gen. nov., sp. nov., a member of the family Alteromonadaceae isolated from marine water of the Arabian Gulf. (PubMed, Int J Syst Evol Microbiol) - "nov., is proposed. The type strain is B66 (=QCC B003/17=LMG 30288 =CCUG 70703)."

Journal

B003: Phase I Clinical Study in the Treatment of HER2-positive Recurrent or Metastatic Breast Cancer (clinicaltrials.gov) - P1; N=45; Recruiting; Sponsor: Shanghai Pharmaceuticals Holding Co., Ltd; Not yet recruiting ➔ Recruiting; Trial completion date: Apr 2020 ➔ Sep 2021; Trial primary completion date: Mar 2020 ➔ May 2021

Clinical • Enrollment open • Trial completion date • Trial primary completion date • Breast Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Oncology • Solid Tumor